revolutionizing vascular access
« aXess » restorative graft
Aditlys develops a novel vascular access graft using a unique material technology
Aditlys’ grafts utilize a porous material made of a patented biodegradable polymer.
Once implanted, the device triggers a unique process of tissue restoration, called Endogenous Tissue Restoration, or ETR, that eventually leads to the resorption of the graft and its replacement by an actual blood vessel.
With this particular approach, Aditlys is expecting to reduce the complications faced routinely by the patients undergoing hemodialysis. The ambition is to define a new standard of care for vascular access that will improve the quality of life of millions of people.
Early stage developments are done and the project is currently entering its final phase.
Aditlys is bringing a game changing technology in a market estimated to be worth a few billion dollars.
- Current Vascular Access
- Etr Technology
PLEASE SELECT ONE OF THE ABOVE OPTIONS TO LEARN MORE
Today, there are more than 3 million persons in the world that are in the terminal stage of renal disease (ESRD patients), meaning that their kidneys are not functional anymore. This is a life-threatening condition, as dangerous levels of waste products accumulate in the blood, threatening the organs.
Some of those patients (2%) will be able to benefit from a renal transplantation. But compatibility issues and a shortage of donors means that most of them will in fact have to wait for years and undergo hemodialysis in the meantime.
3 to 4 times a week, by sessions of 5 to 6 hours on average, they will get connected to a machine, a dialyzer, that will pump and clean their blood. For that to happen, however, an access path must be developed prior to the first treatment to ensure sufficient flow make it to the machine.
3 treatment options are currently available for patients suffering from ESRD.
The surgical creation of an arteriovenous fistula: in this process, the surgeon will connect a vein and an artery in the forearm of the patient. This will increase the flow in the vein to the desired level, expanding it by the same occasion and forming a “pocket” through which the nurse will be able to puncture. This approach is currently the gold standard, as it offers the longest patency with the lowest re-intervention rate. But the puncture cannot be performed before the “pocket” has stabilized, which takes some time, usually 4 to 6 months, time during which the patients are usually treated using a central catheter.
The implantation of an arteriovenous graft: in this situation, the connection between the vein and the artery is done using a graft made of synthetic material. The device is designed so that the nurse can puncture directly through the graft, saving weeks of maturation. This solution is a good alternative for patients with no vein available for the creation of a fistula. Yet, it does come as well with a very high cost: the risk of infection is much higher than with a fistula and 50 % of grafts become occluded before the end 6th month.
The use of a central venous catheter: in this situation, a catheter will be placed via the jugular or subclavian veins. This solution is immediately available and almost systematically used in the event of an emergency. Yet, the trans-dermal positioning is a door open to infections and the complications are potentially very severe. This approach is preferably used as a short term or last resort solution.
To tackle those issues, Aditlys is developing a novel graft, made of very specific polymer. This material comes from Nobel Prize awarded research and is the result of over a decade of Research and Development.
As it is implanted, the contact with blood will trigger a process called Endogenous Tissue Restoration, or ETR: the patient’s natural healing response develops tissue that will fill the porous structure of the graft. But as this process occurs, the material will also resorb, eventually resulting in an actual blood vessel made from the patient’s own cells.
This is the uniqueness of Aditlys’ approach: the implant works as a normal vascular access graft once implanted but turns into a fistula after a few months.
This approach may help to combine the short- and long-term advantages of both existing options, eventually improving the quality of life of millions of patients throughout the world.
Once implanted, this graft, made of bioabsorbable polymer, works as a normal medical device that creates an immediately viable access point. However, with ETR, the patient’s natural healing response develops tissue that fills the porous structure of the graft, and develops a new, natural blood vessel. As ETR occurs, the graft is gradually absorbed by the body.
Aditlys’ aXess grafts may help to combine the short- and long-term advantages of existing options and improve the life of millions of patients dependent on dialysis to stay alive.
SILVERE LUCQUIN | CEO
Silvere Lucquin is a medtech entrepreneur and has a background in business and engineering. Prior to Aditlys, Silvere contributed to found CorWave, a fast-growing start-up company based out of Paris and developing innovative cardiac assist devices.
As CorWave’s employee number one, Silvere has been involved in various parts of the project, including recruiting, fund raising and R&D project management.
Silvere notably won the 2016 edition of the Worldwide Innovation Challenge (“Concours Mondial Innovation”) in the “Start-up, Silver economy” category.
Silvere started his career at SpineVision, an SME developing and commercializing innovative spine implants. He holds an MSc from Ecole Polytechnique in France and Imperial College of London in the UK as well as an MBA from INSEAD.
LUKE BURKE | HEAD OF R&D
Luke Burke is the lead R&D expert for the Aditlys project and has been managing development of devices since their inception. Luke brings over 6 years of R&D experience in the fields of regenerative medicine and tissue engineering, including a PhD obtained from Swansea University (UK) on the technique of electrospinning and its application to tissue engineering.
Prior to joining Aditlys, Luke worked as a Senior R&D Engineer for Xeltis B.V., where he worked on developing manufacturing processes and lead research projects for new applications of the Xeltis technology platform. Luke started his career at Avectas Life Sciences in Dublin, ROI on bespoke engineering projects for institutions including Harvard Medical, Brigham & Women's Hospital, and Massachusetts Institute of Technology. Luke holds a PhD in chemical engineering and has authored a range of articles in peer-reviewed scientific journals.
MARC SOLA | CHAIRMAN OF THE BOARD
As the chairman of Aditlys, Marc Sola brings over 20 years of experience as an entrepreneur. Marc started his first company at the age of 20 and has since founded, or co-founded, a number of businesses in different fields and multiple countries.
Marc holds a Masters of Law degree from the University of Zurich and serves on the board of various companies. Mr. Sola is a sought after speaker at international investment, asset protection and estate planning conferences worldwide. Furthermore, he has published a variety of professional articles and co-authored the book, The Insured Portfolio, published by John Wiley & Sons (2010). He is a member of YPO (Young Presidents Organization), Zurich Chapter.
LAURENT GRANDIDIER | DIRECTOR
Laurent Grandidier is a Director on the board of Aditlys and a Medtech entrepreneur who brings over 15 years of experience as a business leader in the industry. Laurent is the CEO of Xeltis, a fast-growing company developing heart valves using the ETR technology. For 7 years, Laurent has transformed the company from a small research entity into one of the most promising medical device companies globally. In 2015, he notably led an oversubscribed series B financing round of over $30 million.
Prior to Xeltis, Laurent occupied various leadership positions in companies such as Endosense, Guidant/Boston Scientific and Teleflex Medical. Laurent is also co-founder of one of France’s first social venture funds, Investir&+, where he currently sits on the supervisory board. He is a board member of the Frédérique Constant Foundation, supporting pediatric clinical and research centers for treatment of children and young people with heart diseases in countries where such facilities are unavailable.
De Lismortel 31
55 Boulevard Vincent Auriol